NASDAQ: NEO · Diagnostics & Research
NeoGenomics (NEO) fair value: undervalued or overvalued?
As of 27 Sep 2026, Faircurve's model values NeoGenomics (NEO) at $27.38 a share. The stock last closed at $18.47, which puts the model's fair value 48.2% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 2 Oct 2026. NeoGenomics, Inc.
Faircurve Insights · 27 Sep 2026
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia.
Faircurve's model found a fair value of $27.38 a share on 27 Sep 2026, the midpoint of 2,000 simulations. The fair value moved -3.4% from the previous run on 19 Sep 2026, which gave $28.34. The calibrated range is $22.97 to $33.38, built from the fair value since there is no live options data for the stock, and ranges built this way held the price 60% of the time at this horizon. The model's evidence grade is Medium.
The company's overall quality score is 44 out of 100 against comparable companies. The model compares it with Sotera Health Company (SHC), Charles River Laboratories International, Inc. (CRL), Revvity, Inc. (RVTY), Medpace Holdings, Inc. (MEDP), and Quest Diagnostics Incorporated (DGX). The median size of moves around the last 8 earnings reports, ignoring direction, was 10.8%.
Written from the figures on this page for the 27 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give NEO?
The calibrated range for NEO over 63 trading days is $22.97 to $33.38. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The price is below this range. For names with fair value 30%+ above price, the calibrated range has held the price 29% of the time over 63 trading days, and 71% ended below it; the typical move was +5.7%.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $21.86 to $33.23. In 91% of the simulations the fair value came out above the price the model ran on.
How does NEO score on business quality?
NeoGenomics's overall quality score is 44 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 35 | -5.8%ROIC | -3.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 25 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 55 | 10.1%Revenue growth, trailing | 20.3% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 75 | 4.6%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 12 | 23.50xNet debt / EBITDA | 3.50x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 83 | 6.0 ptsEBITDA margin downside volatility, 5y | 11.3 pts |
How does NEO compare with similar companies?
The companies in diagnostics & research closest to NeoGenomics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| VCYT Veracyte, Inc. | $45.81 | $45.56 | -0.5% | Low evidence grade |
| SHC Sotera Health Company | $18.22 | $24.67 | +35.4% | Undervalued |
| RDNT RadNet, Inc. | $69.93 | $64.22 | -8.2% | Low evidence grade |
| CRL Charles River Laboratories International, Inc. | $290.19 | $401.77 | +38.5% | Undervalued |
| RVTY Revvity, Inc. | $151.53 | $164.68 | +8.7% | Fairly valued |
| MEDP Medpace Holdings, Inc. | $599.47 | $680.99 | +13.6% | Fairly valued |
| LH Labcorp Holdings Inc. | $308.49 | $303.65 | -1.6% | Low evidence grade |
| DGX Quest Diagnostics Incorporated | $233.33 | $280.88 | +20.4% | Undervalued |
All diagnostics & research stocks ranked by gap to fair value
When does NEO report earnings, and how has the stock reacted?
NeoGenomics's next earnings report is scheduled for 27 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 9.5% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How NEO moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 10.8%.
| Report date | Two session move |
|---|---|
| 28 Jul 2026 | +16.2% |
| 28 Apr 2026 | +4.1% |
| 17 Feb 2026 | -9.8% |
| 28 Oct 2025 | +1.2% |
| 29 Jul 2025 | -21.1% |
| 29 Apr 2025 | -21.3% |
| 18 Feb 2025 | -11.8% |
| 5 Nov 2024 | +9.3% |
NeoGenomics at a glance
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia.
- Market value
- $497M
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $864M
- Consensus revenue growth, next fiscal year
- +10.6%
- Analysts with estimates
- 7
- Beta to the US market
- 0.75
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices NeoGenomics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for NEO was $28.34. As of 27 Sep 2026 it is $27.38, a change of -3.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about NeoGenomics's valuation
Is NeoGenomics stock undervalued or overvalued?
On Faircurve's model, NEO reads as Undervalued as of 27 Sep 2026. The model's fair value is $27.38 a share against a last close of $18.47, a gap of +48.2%.
What is NEO's fair value?
$27.38 a share as of 27 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $21.86 to $33.23.
What price range does the model give NEO?
$22.97 to $33.38 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does NeoGenomics report earnings next?
The next report is scheduled for 27 Oct 2026. Companies can move their dates.
How much has NEO moved on past earnings reports?
Across its last 8 reports the median two session move was 10.8%, ignoring direction. The largest was -21.3% around the report of 29 Apr 2025.
How confident is the model in this valuation?
The model's evidence grade for NEO is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.